Question follow-through · 98391
Digital Technology: Older People
To ask the Secretary of State for Science, Innovation and Technology, what steps she has taken to reduce the rate of digital exclusion among elderly people in a) England and b) Romford constituency.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department for Science, Innovation and Technology
- Tabled
- 9 Dec 2025
- Target answer date
- 11 Dec 2025
- Answer
- 17 Dec 2025 · 8 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Recorded timeline
9 Dec 2025
Question tabled
To ask the Secretary of State for Science, Innovation and Technology, what steps she has taken to reduce the rate of digital exclusion among elderly people in a) England and b) Romford constituency.
11 Dec 2025
Target answer date
Date supplied by the official written-questions record.
17 Dec 2025
Answer published
We know that digital exclusion is a complex issue and some demographics are more likely to be digitally excluded than others, including older people – with statistics showing 86% of adults aged 60+ are online, compared to 95% of all UK adults in 2025 (202...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Animal Experiments: Dogs
22 Jun 2026 · To ask the Secretary of State for Science, Innovation and Technology, if he will take steps to reduce the number of canines used in scientific trials..
Animal Experiments: Dogs
7 Jul 2026 · To ask the Secretary of State for Science, Innovation and Technology, with reference to the Answer of 30 June 2026 to Question 11617, what her planned timeline is for the regulatory acceptance of alternatives in pharmacokinetic and cardiovascular safety s